Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Silent atrial fibrillation detected by home-monitoring: Cardiovascular disease and stroke prevention in patients with diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Peripheral, synaptic and central neuronal transmission is affected in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Aims: Lipoprotein(a)(Lp(a)) has emerged as an independent risk marker for cardiovascular disease (CVD) in the general population and among persons with existing CVD. We investigated associations between serum Lp(a)concentrations and renal function decline, incident CVD and all-cause mortality in individuals with type 2 diabetes (T2D) and microalbuminuria. Methods: Prospective study including 198 individuals with T2D, microalbuminuria and no CVD. Yearly p-creatinine was measured after baseline in 176 of the participants. The renal endpoint was defined as decline in eGFR of >30% from baseline. CVD events and mortality were tracked from national registries. Cox regression analyses were applied both unadjusted and adjusted for traditional risk factors (sex, age, systolic blood pressure, LDL-cholesterol, smoking, HbA1c, creatinine and urinary albumin creatinine ratio (UAER)). Results: Baseline mean (SD) age was 59 (9)years, eGFR 89 (17) mL/min/1.73 m2, 77% were male, and median [IQR] UAER was 103 [38–242] mg/24-h. Median Lp(a)was 8.04 [3.42–32.3] mg/dL. Median follow-up was 6.1 years; 38 CVD events, 26 deaths and 43 renal events were recorded. For each doubling of baseline Lp(a), the following hazard ratios (95% confidence intervals) were found before and after adjustment respectively: 0.98 (0.84–1.15) and 1.01 (0.87–1.18) for decline in eGFR > 30%, 0.96 (0.81–1.13) and 0.99 (0.82–1.18) for CVD events, 1.04 (0.85–1.27) and 1.06 (0.87–1.30) for all-cause mortality. Conclusions: In this cohort of individuals with T2D and microalbuminuria, the baseline concentration of Lp(a)was not a risk marker for renal function decline, CVD events or all-cause mortality.

Original languageEnglish
Article number107593
JournalJournal of Diabetes and its Complications
Volume34
Issue number7
ISSN1056-8727
DOIs
Publication statusPublished - 1 Jul 2020

    Research areas

  • Cardiovascular, Diabetes, Kidney, Lipoprotein(a), Mortality, Prospective

ID: 59809716